Uncertainty Quantification in Alzheimer's Disease Progression Modeling
0
Sign in to get full access
Overview
- The paper focuses on quantifying uncertainty in Alzheimer's disease progression modeling.
- It explores techniques to capture the inherent variability and unpredictability in the disease's trajectory.
- The researchers aim to improve the reliability and robustness of Alzheimer's disease prediction models.
Plain English Explanation
Alzheimer's disease is a complex condition that affects how the brain functions over time. Predicting the course of Alzheimer's can be challenging because each person's experience with the disease can vary greatly. This paper looks at ways to better account for this uncertainty when building models to forecast the progression of Alzheimer's.
The key idea is to develop modeling approaches that can capture the inherent unpredictability in how Alzheimer's affects individuals. By quantifying this uncertainty, the researchers hope to create more reliable and robust predictive models. This could lead to improved decision-making and care planning for those living with Alzheimer's.
Technical Explanation
The paper focuses on uncertainty quantification in Alzheimer's disease progression modeling. The authors explore techniques to better represent the variability and unpredictability in how the disease manifests and advances over time.
The researchers used longitudinal data on Alzheimer's patients to train various machine learning models, including Gaussian processes and Bayesian neural networks. These models were designed to not only provide point estimates of disease progression, but also capture the inherent uncertainty around those predictions.
By quantifying this uncertainty, the models can convey the likelihood of different outcomes, rather than just a single, deterministic forecast. This additional information can help clinicians and patients make more informed decisions about treatment and care planning.
The paper also discusses the importance of interpretability in these uncertainty-aware models, so that the sources of variability can be better understood.
Critical Analysis
The paper acknowledges several limitations and areas for future research. For example, the models were trained on a relatively small dataset, which may limit their generalizability. Additionally, the paper does not explore how to effectively communicate the uncertainty information to end users, such as clinicians and patients.
Further research could investigate ways to build trust in AI-powered medical decision support systems that incorporate uncertainty quantification. Exploring how to seamlessly integrate these models into clinical workflows and decision-making processes would also be valuable.
Conclusion
This paper advances the field of Alzheimer's disease modeling by focusing on quantifying the inherent uncertainty in the disease's progression. By developing techniques to capture this variability, the researchers aim to create more reliable and robust predictive tools. This could lead to improved care planning and decision-making for those living with Alzheimer's.
The insights from this work could also be applied to other complex, heterogeneous diseases, where accounting for uncertainty is critical for effective clinical management and patient outcomes.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
0
Uncertainty Quantification in Alzheimer's Disease Progression Modeling
Wael Mobeirek, Shirley Mao
With the increasing number of patients diagnosed with Alzheimer's Disease, prognosis models have the potential to aid in early disease detection. However, current approaches raise dependability concerns as they do not account for uncertainty. In this work, we compare the performance of Monte Carlo Dropout, Variational Inference, Markov Chain Monte Carlo, and Ensemble Learning trained on 512 patients to predict 4-year cognitive score trajectories with confidence bounds. We show that MC Dropout and MCMC are able to produce well-calibrated, and accurate predictions under noisy training data.
Read more8/28/2024
🤿
0
Multimodal hierarchical multi-task deep learning framework for jointly predicting and explaining Alzheimer disease progression
Sayantan Kumar, Sean Yu, Andrew Michelson, Thomas Kannampallil, Philip Payne
Objective: We aimed to develop and validate a novel multimodal framework HiMAL (Hierarchical, Multi-task Auxiliary Learning) framework, for predicting cognitive composite functions as auxiliary tasks that estimate the longitudinal risk of transition from Mild Cognitive Impairment (MCI) to Alzheimer Disease (AD). Methods: HiMAL utilized multimodal longitudinal visit data including imaging features, cognitive assessment scores, and clinical variables from MCI patients in the Alzheimer Disease Neuroimaging Initiative (ADNI) dataset, to predict at each visit if an MCI patient will progress to AD within the next 6 months. Performance of HiMAL was compared with state-of-the-art single-task and multi-task baselines using area under the receiver operator curve (AUROC) and precision recall curve (AUPRC) metrics. An ablation study was performed to assess the impact of each input modality on model performance. Additionally, longitudinal explanations regarding risk of disease progression were provided to interpret the predicted cognitive decline. Results: Out of 634 MCI patients (mean [IQR] age : 72.8 [67-78], 60% men), 209 (32%) progressed to AD. HiMAL showed better prediction performance compared to all single-modality singe-task baselines (AUROC = 0.923 [0.915-0.937]; AUPRC= 0.623 [0.605-0.644]; all p<0.05). Ablation analysis highlighted that imaging and cognition scores with maximum contribution towards prediction of disease progression. Discussion: Clinically informative model explanations anticipate cognitive decline 6 months in advance, aiding clinicians in future disease progression assessment. HiMAL relies on routinely collected EHR variables for proximal (6 months) prediction of AD onset, indicating its translational potential for point-of-care monitoring and managing of high-risk patients.
Read more5/7/2024
0
Learning the irreversible progression trajectory of Alzheimer's disease
Yipei Wang, Bing He, Shannon Risacher, Andrew Saykin, Jingwen Yan, Xiaoqian Wang
Alzheimer's disease (AD) is a progressive and irreversible brain disorder that unfolds over the course of 30 years. Therefore, it is critical to capture the disease progression in an early stage such that intervention can be applied before the onset of symptoms. Machine learning (ML) models have been shown effective in predicting the onset of AD. Yet for subjects with follow-up visits, existing techniques for AD classification only aim for accurate group assignment, where the monotonically increasing risk across follow-up visits is usually ignored. Resulted fluctuating risk scores across visits violate the irreversibility of AD, hampering the trustworthiness of models and also providing little value to understanding the disease progression. To address this issue, we propose a novel regularization approach to predict AD longitudinally. Our technique aims to maintain the expected monotonicity of increasing disease risk during progression while preserving expressiveness. Specifically, we introduce a monotonicity constraint that encourages the model to predict disease risk in a consistent and ordered manner across follow-up visits. We evaluate our method using the longitudinal structural MRI and amyloid-PET imaging data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Our model outperforms existing techniques in capturing the progressiveness of disease risk, and at the same time preserves prediction accuracy.
Read more9/2/2024
0
Uncertainty Quantification Using Ensemble Learning and Monte Carlo Sampling for Performance Prediction and Monitoring in Cell Culture Processes
Thanh Tung Khuat, Robert Bassett, Ellen Otte, Bogdan Gabrys
Biopharmaceutical products, particularly monoclonal antibodies (mAbs), have gained prominence in the pharmaceutical market due to their high specificity and efficacy. As these products are projected to constitute a substantial portion of global pharmaceutical sales, the application of machine learning models in mAb development and manufacturing is gaining momentum. This paper addresses the critical need for uncertainty quantification in machine learning predictions, particularly in scenarios with limited training data. Leveraging ensemble learning and Monte Carlo simulations, our proposed method generates additional input samples to enhance the robustness of the model in small training datasets. We evaluate the efficacy of our approach through two case studies: predicting antibody concentrations in advance and real-time monitoring of glucose concentrations during bioreactor runs using Raman spectra data. Our findings demonstrate the effectiveness of the proposed method in estimating the uncertainty levels associated with process performance predictions and facilitating real-time decision-making in biopharmaceutical manufacturing. This contribution not only introduces a novel approach for uncertainty quantification but also provides insights into overcoming challenges posed by small training datasets in bioprocess development. The evaluation demonstrates the effectiveness of our method in addressing key challenges related to uncertainty estimation within upstream cell cultivation, illustrating its potential impact on enhancing process control and product quality in the dynamic field of biopharmaceuticals.
Read more9/5/2024